FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Effect of Cardioprotection on the Right Ventricular Function in Breast Cancer Patients Receiving Potentially Cardiotoxic Therapy: A SAFE Trial Substudy. PMID 40965835 · Echocardiography · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomised Controlled Trial on the Treatment of Recurrent Implantation Failure Women Who Failed Egg Donation Cycles Using Low-Dose GM-CSF. PMID 40965804 · Am J Reprod Immunol · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3. PMID 40955720 · Alzheimers Dement · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Efficacy and Safety of Amyloid Beta-Directed Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials. PMID 40951935 · Hum Psychopharmacol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE. PMID 40940567 · Ann Hematol · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Multiplicity Control in Oncology Clinical Trials With a Binary Surrogate Endpoint-Based Drop-The-Losers Design. PMID 40911375 · Stat Med · 2025-Sep The record describes a methodological study evaluating a 'drop-the-losers' adaptive design strategy for dose selection in oncology, including simulations and a lung cancer trial design example. While it mentions Phase II/III contexts and randomized elements, it does not present results from a specific Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The abstract focuses on multiplicity control, design evaluation, and software, not on reporting trial efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies. PMID 40910999 · Expert Opin Biol Ther · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Reduction in Dressing Change Burden in Patients With Epidermolysis Bullosa-Impact of Oleogel-S10. PMID 40908727 · J Dermatol · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor. PMID 40908570 · Cancer Med · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer. PMID 40907528 · Lancet Oncol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial. PMID 40907518 · Lancet Oncol · 2025-Sep The trial is a Phase 3 randomized oncology study with drug interventions, but the primary endpoint is chronic toxicity, not a time-to-event efficacy endpoint. No time-to-event efficacy results (OS, PFS, DFS, etc.) or associated Kaplan-Meier/HR data are reported in the abstract. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial. PMID 40907514 · Lancet Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Quality assurance and reporting for FLASH clinical trials: The experience of the FEATHER trial. PMID 40904039 · Med Phys · 2025-Sep The record describes a protocol and methodology paper for a quality assurance program in a randomized phase II/III trial conducted in domestic animals, not a human trial. It does not report any time-to-event efficacy results or involve a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial. PMID 40896880 · ESMO Open · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study. PMID 40896462 · EClinicalMedicine · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer. PMID 40893054 · JCO Precis Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab. PMID 40886121 · ACR Open Rheumatol · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Real-time non-invasive localization in sub-lobar resection for small pulmonary nodules: a noninferiority randomized clinical trial. PMID 40865372 · Lung Cancer · 2025-Sep This is a randomized trial for a surgical technique (non-invasive localization) in lung cancer, not a drug intervention. It lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Feasibility of non-routine abdominal drainage for minimally invasive liver surgery: study protocol for a multicenter randomized controlled clinical trial. PMID 40860204 · Int J Surg Protoc · 2025-Sep 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Endovascular Therapy Versus Medical Management for Large Ischemic Infarct: 1-Year Outcomes of the ANGEL-ASPECT Trial. PMID 40854041 · Stroke · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B. PMID 40848527 · JACC Adv · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Modified Atkins diet versus topiramate in young children with epileptic spasms refractory to steroids and vigabatrin: a randomised open-label trial. PMID 40840039 · Seizure · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study. PMID 40831469 · EClinicalMedicine · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Effect of Preoperative Magnetic Resonance Imaging on Long-term Oncological Outcomes Following Radical Prostatectomy-A 12-year Follow-up of a Randomized Controlled Trial. PMID 40823001 · Eur Urol Open Sci · 2025-Sep 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial. PMID 40818473 · Lancet Neurol · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Switching Therapy From Alglucosidase Alfa to Avalglucosidase Alfa on Respiratory Function in Participants With Late-Onset Pompe Disease: A Post Hoc Analysis From the COMET Trial. PMID 40799512 · JIMD Rep · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effects of Prenatal DHA Dose on Infant Visual Attention. PMID 40791013 · Dev Psychobiol · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged ≥50 years with a history of herpes zoster: A phase 3, randomized controlled trial. PMID 40780591 · J Infect · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparison between cap-aspiration lumpectomy versus endoscopic submucosal dissection for the treatment of small gastric submucosal tumors: a prospective randomized controlled trial. PMID 40775469 · Surg Endosc · 2025-Sep The study is a randomized, prospective trial comparing two endoscopic surgical techniques (cap-aspiration lumpectomy vs. endoscopic submucosal dissection) for small gastric submucosal tumors. It is not a Phase III/IIIb or Phase II/III trial, does not involve a drug-containing intervention, and reports surgical/technical outcomes (resection time, cost, complications) without a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol for Log2Lose: A randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity. PMID 40774423 · Contemp Clin Trials · 2025-Sep 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Theta burst stimulation of temporo-parietal cortex regions for the treatment of persistent auditory hallucinations: a multicentre, randomised, sham-controlled, triple-blind phase 3 trial in Germany. PMID 40774272 · Lancet Psychiatry · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial. PMID 40774040 · Lung Cancer · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial. PMID 40773982 · Oral Oncol · 2025-Sep The record is a pilot randomized controlled trial for a lymphedema and fibrosis self-management program in head and neck cancer survivors. It is oncology and human, and it is randomized. However, it fails multiple key eligibility criteria: it is a pilot study (not definitive Phase III/IIIb or Phase II/III), it does not involve a drug intervention, and it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. PMID 40763418 · Gynecol Oncol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Associations between progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) and survival in patients with limited-stage small cell lung cancer (LS SCLC) receiving chemoradiotherapy (CRT). PMID 40763415 · Lung Cancer · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A systematic review of the efficacy of cancer vaccines in advanced breast cancer. PMID 40762664 · Breast Cancer · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial. PMID 40759025 · Ann Intern Med · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial. PMID 40752730 · Actas Urol Esp (Engl Ed) · 2025-Sep The record is a protocol for a Phase III randomized trial with a drug intervention and a time-to-event endpoint, but it does not report formal results. It is excluded as a protocol without results. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. PMID 40752515 · Lancet Oncol · 2025-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy. PMID 40752049 · Maturitas · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Description of a cruciferous vegetable intervention trial to test the efficacy of a maintenance component to reduce bladder cancer recurrence and progression. PMID 40750073 · Contemp Clin Trials · 2025-Sep The record is a protocol for a randomized controlled trial testing a dietary intervention for bladder cancer. It is not a report of results, does not involve a drug intervention, and does not assess a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial. PMID 40746973 · Lancet Reg Health Southeast Asia · 2025-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| [Anti-CD19 treatment: the new gold standard for IgG4-related diseases]. PMID 40745228 · Z Rheumatol · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. PMID 40743487 · Neurol Neuroimmunol Neuroinflamm · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Five-Year Experience of Etanercept as Adjunct to Intravenous Immunoglobulin for Kawasaki Disease with Coronary Artery Involvement. PMID 40741226 · J Pediatr Clin Pract · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Short-term outcomes of nonintubated and intubated video-assisted thoracoscopic surgery in management of malignant pleural effusion. PMID 40739892 · Asian Cardiovasc Thorac Ann · 2025-Sep The record describes a randomized comparison of two procedural techniques (nonintubated vs intubated VATS) for managing malignant pleural effusion. It does not involve a drug-containing intervention (the intervention is surgical technique with anesthesia type). The primary endpoints are short-term postoperative outcomes (pain scores, dyspnea, radiographic findings), not time-to-event efficacy endpoints like OS, PFS, DFS, etc., and no Kaplan-Meier survival curves or hazard ratios are reported. Therefore, it fails two key eligibility criteria: drug intervention and time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials. PMID 40736113 · Liver Int · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results. PMID 40728772 · Am J Clin Dermatol · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial. PMID 40720835 · Ann Intern Med · 2025-Sep 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. PMID 40717455 · Aliment Pharmacol Ther · 2025-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |